Compositions and methods for treating cancer using RHOA dominant negative forms
AssigneeDana-Farber Cancer Institute, Inc.
InventorsAdam Bass, Haisheng Zhang
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating cancers with reduced or absent CDH1 using a RHOA dominant negative polypeptide or biologically active fragment thereof, and/or a nucleic acid encoding a RHOA dominant negative polypeptide or biologically active fragment thereof.
Claims14
A method of treating a subject afflicted with cancer that has a reduced level of CDH1, comprising administering to the subject a therapeutically effective amount of at least one agent selected from the group consisting of 1) a nucleic acid encoding a RHOA dominant negative polypeptide encoding the sequence of SEQ ID NO:
- 1 and 2) a RHOA dominant negative polypeptide having the sequence of SEQ ID NO:
- 1.
A method of reducing viability or proliferation of cancer cells which have a reduced level of CDH1, comprising contacting the cancer cells with at least one agent selected from the group consisting of 1) a nucleic acid encoding a RHOA dominant negative polypeptide encoding the sequence of SEQ ID NO:
- 1 and 2) a RHOA dominant negative polypeptide having the sequence of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.